Carevive by Health Catalyst™’s Post

Carevive by Health Catalyst™ is excited to be participating in the upcoming IMPACCT Real World Evidence (RWE) Summit in Boston, MA, October 29-31, 2024. Aaron Galaznik, MD, will be featured in a panel discussion with other leading experts in RWE and will present on “Digital ePRO Platform for Capturing Patient Perspectives and Proactively Managing Treatment Burden in Real-World Oncology Care Settings.” Dr. Galaznik will highlight how Carevive SMART DATA®, which features weekly patient reported outcomes data (PROs) on symptoms, physical function, quality of life and treatment bother merged with a complete set of EMR-derived datapoints, offers unparalleled insights into patient outcomes, clinical management, and health system impact, leading to many new use cases that can be explored. As the panel discussion will demonstrate, Carevive SMARTData® empowers life science companies to put our data into action across the enterprise and improve the patient experience. Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Hanson Wade Group #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

Continuing our Carevive SMARTData™ FAQ Series... ❓ FAQ:  What kinds of PROs are being collected? Do you only use validated instruments? ✅ANSWER: Carevive has developed an industry leading set of cancer registries that are focused on the longitudinal patient experience, with more than 30 cancer types available. Carevive SMART DATA™ features weekly patient reported outcomes data (PROs) on symptoms, physical function, quality of life, and treatment bother, merged with a robust set of EMR-derived datapoints. As such, Carevive SMARTData™ empowers life science companies to put our data into action across the enterprise and improve the patient experience. The majority of PRO surveys included in Carevive SMARTData™ are fully validated instruments, such as PRO-CTCAE, PROMIS, and GP5. Our datasets offer unparalleled insights into patient outcomes, clinical management, and health system impact, leading to many new use cases that can be explored. 👉 Check out our post next week to learn more about these use cases and how they can enrich your data assets. Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare  #oncology #patientreportedoutcomes #oncologydata  #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata 

Keep up with our Carevive SMARTData™ FAQ series to gain deeper insights into Data in Action. Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

Keep up with our Carevive SMARTData™ FAQ series to gain deeper insights into Data in Action.

Carevive by Health Catalyst™ is excited to be participating in this year’s IMPACCT Real World Evidence (#RWE) Summit in Boston, MA, October 29-31, 2024. Aaron Galaznik, MD, will be featured in a panel discussion with other leading experts in RWE. Dr. Galaznik will highlight how Carevive SMART DATA®, which features weekly patient reported outcomes data (PROs) on symptoms, physical function, quality of life, and treatment bother merged with a complete set of EMR-derived datapoints, offers unparalleled insights into patient outcomes, clinical management, and health system impact, leading to many new use cases that can be explored.   As the panel discussion will demonstrate, Carevive SMARTData® empowers life science companies to put our data into action across the enterprise and improve the patient experience. Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

Part 4 of the Carevive SMARTData™ FAQ Series ❓FAQ: What kinds of use cases can be analyzed with Carevive SMARTData™?   ✅ ANSWER: As discussed in last week’s post, Carevive has developed an industry-leading set of cancer registries that are focused on the longitudinal patient experience, with more than 30 cancer types available. By combining weekly patient reported outcomes data (PROs) on symptoms, physical function, quality of life, and treatment bother, merged with a complete set of EMR-derived datapoints, Carevive SMARTData™ empowers life science companies to put our data into action across the enterprise and improve the patient experience through the exploration of a wide range of use cases. Some of the topics that can be analyzed from this dataset include tolerability, quality of life, symptom burden, discontinuation/adherence, and frailty. These insights are being used by stakeholders from commercial, value and evidence, and clinical development to address questions related to standard of care, healthcare utilization, and clinical trial planning.   Aaron Galaznik Emelly Rusli Keri Collette Mordecai Kramer Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare  #oncology #patientreportedoutcomes #oncologydata  #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata 

Carevive recently launched a new data set, Carevive SMARTAlerts™, a unique and indispensable companion to our industry-leading longitudinal Patient-Reported Outcome (PRO) registry data.    This innovative dataset goes beyond traditional records, providing crucial information about the care team's response to severe symptoms experienced by patients throughout their treatment journey. These alerts offer unparalleled insights into patient outcomes, clinical management, and health system impact, leading to many new use cases that can be explored.   The integration of SMARTAlerts™ with Carevive’s PRO and EMR-extracted demographic data, enables healthcare providers to address challenges more effectively and tailor interventions for optimal patient outcomes, yielding an important new tool for life science companies to put Carevive data into action and improve the patient experience. If you would like more information or to meet with a Carevive representative, please contact us at https://lnkd.in/dddCeNbK. Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Bruno Lempernesse #carevive #digitaloncology #cancer #cancercare  #oncology #patientreportedoutcomes #oncologydata  #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata 

Impact patients with cancer and hold a workshop today with us and explore Data-in-Action to Strengthen Your Oncology Insights in 2024!

Cancer treatment ranges from 4 to 6 months...so a well defined cancer care program should not only provide features like second opinion, diagnostics discounts or standard literature but offer comprehensive guidance to patients and also bring in entire family together to create a care ecosystem for successful outcomes. Our cancer care program start from early stage of creating awareness, to exploring various treatment options, to helping them fully recover using people & proprietary technology platform...Volo Health also offers community support where patients & survivors can share their experiences on common platform. Watch this space for more info! #cancercare #closethecaregap #employeebenefits Mohit Agarwal Tushar Rastogii Shashank Shekhar

🚨 Big Announcement: Join Us LIVE on LinkedIn Today at Noon! 🚨 Are you ready for a game-changing conversation that could reshape the future of healthcare? 🎤 At 12 PM EST today, we’re going LIVE with the one and only Dr. Barbara McAneny, the trailblazer behind the revolutionary “Come Home” initiative that's shaking up the cancer care industry! 💡 Did You Know? The cancer care market is projected to hit $250 billion by 2025, but only 5% of cancers have targeted therapies. Imagine the innovation potential, and hear directly from the leader already making waves! Get ready to dive deep into: How patient-centered care is cutting hospitalizations by up to 30%! Why keeping patients at home could be the future of oncology. What’s next in the $200 billion oncology market — and how you can be part of it! 👉 Don’t miss this chance to engage, ask your burning questions, and discover insights that could transform your perspective on healthcare. 🔥 Mark your calendars, set your reminders, grab your coffee — and join us for an unforgettable LinkedIn Live at noon! Let’s make some noise and show up strong! 🚀 #LinkedInLive #HealthcareRevolution #CancerCare #DrBarbaraMcAneny #5STARBDM #FutureOfHealth #GameChanger #JoinTheConversation eMedEvents - Global Marketplace for CME/CE eMedEd 🔗 Click Here to Join Live at Noon: The link is in the comments below!